Abstract
The Chinese Hypertension Intervention Efficacy Study (CHIEF) is a multi-centre randomized controlled clinical trial comparing the effects of amlodipine+angiotensin II receptor blocker and amlodipine+diuretics on the incidence of cardiovascular events, represented as a composite of non-fatal stroke, non-fatal myocardial infarction and cardiovascular death events in high-risk Chinese hypertensive patients. The study also evaluates the long-term effects of lipid-lowering treatment and lifestyle modification. From October 2007 to October 2008, 13,542 patients were enrolled into the study in 180 centres in China. Patients will be followed up for 4 years. There was no difference in baseline characteristics between the two blood pressure arms.
Publication types
-
Comparative Study
-
Multicenter Study
-
Randomized Controlled Trial
MeSH terms
-
Aged
-
Amiloride / therapeutic use
-
Amlodipine / therapeutic use*
-
Angiotensin II Type 1 Receptor Blockers / therapeutic use*
-
Antihypertensive Agents / therapeutic use*
-
Benzimidazoles / therapeutic use
-
Benzoates / therapeutic use
-
Blood Pressure / drug effects*
-
Calcium Channel Blockers / therapeutic use*
-
Cardiovascular Diseases / etiology
-
Cardiovascular Diseases / mortality
-
Cardiovascular Diseases / physiopathology
-
Cardiovascular Diseases / prevention & control*
-
Chi-Square Distribution
-
China
-
Diuretics / therapeutic use*
-
Drug Therapy, Combination
-
Female
-
Humans
-
Hydrochlorothiazide / therapeutic use
-
Hypertension / complications
-
Hypertension / drug therapy*
-
Hypertension / mortality
-
Hypertension / physiopathology
-
Kaplan-Meier Estimate
-
Male
-
Middle Aged
-
Research Design*
-
Risk Assessment
-
Risk Factors
-
Telmisartan
-
Time Factors
-
Treatment Outcome
Substances
-
Angiotensin II Type 1 Receptor Blockers
-
Antihypertensive Agents
-
Benzimidazoles
-
Benzoates
-
Calcium Channel Blockers
-
Diuretics
-
Hydrochlorothiazide
-
Amlodipine
-
Amiloride
-
Telmisartan